Stock Comparison

ABCL vs UNH

Abcellera Biologics Inc vs UnitedHealth Group Inc

The Verdict

ABCL takes this one.

Winner

ABCL

Abcellera Biologics Inc

7.2

out of 10

Solid Pick

UNH

UnitedHealth Group Inc

0.3

out of 10

Distressed

Head-to-Head

$1.2B

Market Cap

$276.2B

-8.0

P/E Ratio

22.9

-194.9%

Profit Margin

2.7%

-14.8%

Return on Equity

12.5%

0.1

Debt-to-Equity

0.0

Aggressive

Overall Risk

Moderate-High

7.2

DVR Score

0.3

The Deep Dive

ABCL7.2/10

AbCellera continues to hold significant 10x potential, driven by its cutting-edge AI-powered antibody discovery platform and a strategic pivot towards internal drug development. The substantial Q4 2025 revenue beat and the impending Phase 1/Phase 2 data for ABCL635 are strong positive catalysts, de-risking its pipeline and demonstrating execution. While the company still grapples with negative pro...

Full ABCL Analysis

UNH0.3/10

UnitedHealth Group (UNH) remains a healthcare titan, but its sheer scale and the highly regulated nature of its operations fundamentally limit its 10x growth potential within 3-5 years. The recent Optum Health operating loss of $278M in 2025 (compared to $7.77B income in 2024) is a significant concern, eroding the growth narrative that Optum once provided. Furthermore, the proposed 0.09% Medicare ...

Full UNH Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.